Reuters logo
BRIEF-Onxeo ‍announces preclinical data for combination of AsiDNA™ and belinostat​
September 28, 2017 / 6:30 AM / 2 months ago

BRIEF-Onxeo ‍announces preclinical data for combination of AsiDNA™ and belinostat​

Sept 28 (Reuters) - ONXEO SA:

* ‍ANNOUNCES COMPELLING PRECLINICAL DATA IN COMBINATION FOR ITS TWO INNOVATIVE COMPOUNDS, ASIDNA™ AND BELINOSTAT​

* ‍RESULTS DEMONSTRATE VERY STRONG SYNERGISTIC EFFECT BETWEEN ASIDNA, FIRST-IN-CLASS DNA BREAK REPAIR INHIBITOR (DBRI), AND HISTONE DEACETYLASE INHIBITORS (HDACI)​

* ‍POTENTIAL APPLICATION OF ASIDNA™ IN COMBINATION WITH ANY HDACI FULLY COVERED BY KEY WORLDWIDE PATENT APPLICATION​

* PARTICULARLY HIGH SYNERGY FOR COMBINATION OF ITS TWO PROPRIETORY ASSETS, ASIDNA AND BELINOSAT

* HAS PLANNED AN EXTENSIVE PUBLICATION PLAN, STATING AT UPCOMING AACR MEETING IN APRIL 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below